Search
Pareto Securities' Healthcare Conference: Saniona has built expertise in the ion channel space, in addition to its own work, it has partnerships with Jazz, Acadia, and others
CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us...
Sep 16
Pareto Securities' Healthcare Conference: BioArctic's CEO Gunilla Osswald highlights the company's brain transporter technology, the latest on Leqembi, and a Parkinson's program
She describes the transferrin receptor based brain transporter technology, which the company recently signed another new partner...
Sep 16
Pareto Securities' Healthcare Conference: Guard Therapeutics will have a key P2b trial read for its kidney protecting therapy RCM-035 in the 4th quarter - CEO Tobias Agervald walks us through it
He describes the science behind the A1M protein that this is based on, and how Guard has chosen kidney protection for patients who are...
Sep 16
Pareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor
CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and...
Sep 16
Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today
CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus,...
Sep 16
Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week on its first-in-class orexin agonist for treating narcolepsy type 1
Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two...
Sep 12
Humacyte CEO Laura Niklason updates us on the early days of the launch of Symvess, the company's bioengineered blood vessel product
She describes the work the company is doing with hospitals and the military to grow uptake as the company launches the product. Plus,...
Sep 8
Biotech veteran Harvey Berger was named Chairman & CEO of Arena BioWorks today - he describes how 'foraging to focusing' will be the name of the game
Dr. Berger, whose experience in biotech goes back decades, including founding and running ARIAD for 25 years, is taking over this company...
Sep 8
Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS
CEO Neil Miller walks us through the hypothesis of how toxic proteins created by neurodegenerative diseases enter and damage the...
Sep 8
N-Power Medicine launched what it is calling the 'Industry’s First Prospective External Control Arm Platform' for cancer trials - Mark Lee, CEO and a medical oncologist, explains why and how it works
He describes how the idea is to cut down on control arm overlap used in numerous trials. If successful, it might free up space and...
Sep 2
The CEO of Tennr, which raised a $101M series C earlier this summer, explains how the company's platform uses large language models to make the patient referral process to specialists more efficient
Trey Holterman describes how Tennr is trying to fix this process which relies on significant unstructured data and has traditional leads...
Aug 28
After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires
Founder & CEO Ashoka Rejendra describes what the company offers, which is a not only a software package, but guidance on how to build and...
Aug 18
IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead
Dr. Zocca describes the results of the trial, which showed a 19.4 months vs. 11.0 months mPFS benefit versus pembro alone, but narrowly...
Aug 15
Visiting Genezen Indianpolis to see where it all started - and where the company today makes lenti and retroviral vectors for cell and gene therapies
BiotechTV visited our sponsor Genezen's Indianapolis facility last week where they manufacture lenti and retroviral vectors for gene and...
Aug 13
Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced...
Aug 13
Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis
Co-Founder & CEO Jim Martineau walks us through the platform and describes the importance of being cell type specific. The company...
Aug 13
Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter
Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and...
Aug 12
IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year
Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets...
Aug 12
CytomX Therapeutics' years of work on its 'Probody' masking technology may be paying off at a time when there is growing focus on this approach - it presented key initial data on its EpCAM ADC in May
Chairman & CEO Sean McCarthy walks us through the science and describes what CytomX has learned about it over many years of working on...
Aug 11
Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease
CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the...
Aug 11
.png){kind=logo}
